MX2016010056A - 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. - Google Patents
6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.Info
- Publication number
- MX2016010056A MX2016010056A MX2016010056A MX2016010056A MX2016010056A MX 2016010056 A MX2016010056 A MX 2016010056A MX 2016010056 A MX2016010056 A MX 2016010056A MX 2016010056 A MX2016010056 A MX 2016010056A MX 2016010056 A MX2016010056 A MX 2016010056A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- carboxamides
- heteroaryloxy
- quinoline
- aryloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Se describen compuestos de la fórmula (I) (ver Fórmula) y sales, ésteres, amidas, o formas radioetiquetadas farmaceéuticamente aceptables de los mismos, en donde R1, R2, y R3 son como se define en la especificación, que son útiles en tratar afecciones o trastornos que se previenen por o aminoran por los canales de sodio abiertos por voltaje, por ejemplo, NaV1.7 y/o NaV1.8. Se describen métodos para hacer los compuestos. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I), y métodos para usar tales compuestos y composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936397P | 2014-02-06 | 2014-02-06 | |
PCT/US2015/014380 WO2015119998A1 (en) | 2014-02-06 | 2015-02-04 | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010056A true MX2016010056A (es) | 2016-11-15 |
Family
ID=52484589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010056A MX2016010056A (es) | 2014-02-06 | 2015-02-04 | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9452986B2 (es) |
EP (1) | EP3102569A1 (es) |
JP (1) | JP6532474B2 (es) |
KR (1) | KR20160118345A (es) |
CN (1) | CN106458985B (es) |
AU (1) | AU2015214366B2 (es) |
BR (1) | BR112016017996A2 (es) |
CA (1) | CA2938719A1 (es) |
HK (1) | HK1231471A1 (es) |
IL (1) | IL247014A0 (es) |
MX (1) | MX2016010056A (es) |
RU (1) | RU2016135637A (es) |
SG (1) | SG11201606367YA (es) |
WO (1) | WO2015119998A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
DK3805233T3 (da) | 2014-01-13 | 2024-04-15 | Aurigene Oncology Ltd | (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling |
SG11201606367YA (en) * | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
CU20160188A7 (es) * | 2014-06-20 | 2017-06-05 | Aurigene Discovery Tech Ltd | Compuestos de indazole substituidos como inhibidores de irak4 |
JP6715239B2 (ja) * | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換2−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
CA3001075C (en) | 2015-10-07 | 2020-10-27 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Crmp2 sumoylation inhibitors and uses thereof |
JP6779992B2 (ja) * | 2015-10-09 | 2020-11-04 | アッヴィ・エス・ア・エール・エル | N−スルホニル化ピラゾロ[3,4−b]ピリジン−6−カルボキサミドおよび使用法 |
CN110337436A (zh) | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
AU2018242623A1 (en) | 2017-03-31 | 2019-10-17 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
BR112019028181A2 (pt) * | 2017-06-30 | 2020-07-07 | Bayer Animal Health Gmbh | novos derivados de azaquinolina |
SG11202002386WA (en) | 2017-10-31 | 2020-04-29 | Curis Inc | Compounds and compositions for treating hematological disorders |
WO2020054657A1 (ja) | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
CN113302175A (zh) | 2018-11-09 | 2021-08-24 | 维瓦斯治疗公司 | 双环化合物 |
MX2021007967A (es) * | 2019-01-11 | 2021-09-21 | Naegis Pharmaceuticals Inc | Inhibidores de síntesis de leucotrienos. |
TW202104189A (zh) * | 2019-04-16 | 2021-02-01 | 美商維瓦斯治療公司 | 雙環化合物 |
WO2023138599A1 (zh) * | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | 芳香并环类Nav1.8抑制剂及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE548358T1 (de) | 2003-08-05 | 2012-03-15 | Vertex Pharma | Tetrahydrochinazolin-verbindungen als inhibitoren von spannungsabhängigen ionenkanälen |
AU2005299018B2 (en) * | 2004-10-19 | 2011-07-07 | F. Hoffmann-La Roche Ag | Quinoline derivatives |
JP2008540661A (ja) | 2005-05-16 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとしての二環式の誘導体 |
GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
CA2619898C (en) * | 2005-09-01 | 2014-03-18 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
WO2007127183A1 (en) | 2006-04-26 | 2007-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
CN102448937A (zh) * | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
JP5807058B2 (ja) * | 2010-05-10 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | 二機能キノリン誘導体 |
CN106478497B (zh) * | 2010-10-18 | 2020-05-08 | 拉夸里亚创药株式会社 | 作为ttx-s阻滞剂的芳胺衍生物 |
RU2683788C2 (ru) * | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
SG11201606367YA (en) * | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
-
2015
- 2015-02-04 SG SG11201606367YA patent/SG11201606367YA/en unknown
- 2015-02-04 EP EP15705447.9A patent/EP3102569A1/en not_active Withdrawn
- 2015-02-04 WO PCT/US2015/014380 patent/WO2015119998A1/en active Application Filing
- 2015-02-04 BR BR112016017996A patent/BR112016017996A2/pt not_active Application Discontinuation
- 2015-02-04 AU AU2015214366A patent/AU2015214366B2/en not_active Ceased
- 2015-02-04 MX MX2016010056A patent/MX2016010056A/es unknown
- 2015-02-04 CN CN201580017702.3A patent/CN106458985B/zh not_active Expired - Fee Related
- 2015-02-04 JP JP2016550611A patent/JP6532474B2/ja not_active Expired - Fee Related
- 2015-02-04 US US14/613,579 patent/US9452986B2/en active Active
- 2015-02-04 RU RU2016135637A patent/RU2016135637A/ru not_active Application Discontinuation
- 2015-02-04 CA CA2938719A patent/CA2938719A1/en not_active Abandoned
- 2015-02-04 KR KR1020167024669A patent/KR20160118345A/ko not_active Application Discontinuation
-
2016
- 2016-07-28 IL IL247014A patent/IL247014A0/en unknown
- 2016-08-17 US US15/239,554 patent/US9969693B2/en active Active
-
2017
- 2017-05-18 HK HK17105028.6A patent/HK1231471A1/zh unknown
-
2018
- 2018-04-13 US US15/952,682 patent/US20180334435A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170226062A9 (en) | 2017-08-10 |
US20180334435A1 (en) | 2018-11-22 |
CN106458985A (zh) | 2017-02-22 |
CN106458985B (zh) | 2019-05-03 |
AU2015214366A1 (en) | 2016-08-18 |
JP2017505327A (ja) | 2017-02-16 |
RU2016135637A3 (es) | 2018-08-27 |
RU2016135637A (ru) | 2018-03-12 |
US20150218102A1 (en) | 2015-08-06 |
US9969693B2 (en) | 2018-05-15 |
KR20160118345A (ko) | 2016-10-11 |
HK1231471A1 (zh) | 2017-12-22 |
JP6532474B2 (ja) | 2019-06-19 |
US9452986B2 (en) | 2016-09-27 |
AU2015214366B2 (en) | 2019-04-18 |
EP3102569A1 (en) | 2016-12-14 |
SG11201606367YA (en) | 2016-09-29 |
IL247014A0 (en) | 2016-09-29 |
US20160355482A1 (en) | 2016-12-08 |
WO2015119998A1 (en) | 2015-08-13 |
BR112016017996A2 (pt) | 2017-08-08 |
CA2938719A1 (en) | 2015-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
MX2017005663A (es) | Tetrahidropiranos sustituidos y metodo de uso. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
MY193728A (en) | Muscarinic receptor agonists | |
MX2018004664A (es) | Antagonistas de ep4. | |
WO2017177004A8 (en) | Tertiary amides and method of use | |
MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
IN2014DN09347A (es) | ||
MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
WO2018039077A8 (en) | Therapeutic compounds | |
SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
MX2017003458A (es) | Indazol ureas y metodo de uso. | |
MX2017001603A (es) | Derivados de piperazina como moduladores de los receptores x del higado. | |
TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
MY197595A (en) | Alkyl dihydroquinoline sulfonamide compounds |